Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

Targeted Oncology

Volumn 10, Issue 2, 2015, Pages 247-253

  Bosc, Cecile ^a   Ferretti, Gilbert R ^b   Cadranel, Jacques ^c   Audigier Valette, Clarisse ^d   Besse, Benjamin ^e   Barlesi, Fabrice ^f   Decroisette, Chantal ^g   Lantuejoul, Sylvie ^a   Arbib, François ^a   Moro Sibilot, Denis ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c HÔPITAL TENON   (France)

^d Sainte Musse Hospital   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g Centre Hospitalier de la Region d'Annecy   (France)

Author keywords

Acquired resistance; ALK rearrangement; EGFR mutant lung cancer; Molecular diagnosis; Targeted therapy

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTICOAGULANT AGENT; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; COHORT ANALYSIS; CYTOPATHOLOGY; DISEASE COURSE; DISTANT METASTASIS; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOSCOPIC BIOPSY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; GENE REARRANGEMENT; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSBRONCHIAL ASPIRATION; TREATMENT RESPONSE; TUMOR BIOPSY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FRANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; MUTATION; PATHOLOGY; PREDICTIVE VALUE; SECONDARY; SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FRANCE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; ONCOGENE PROTEINS, FUSION; ONCOGENES; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930538309     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0332-y     Document Type: Article

References (31)

1. Thun MJ, Hannan LM, Adams-Campbell LL et al (2008) Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 5(9):e185
2. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98
3. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566
4. Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004–1012
5. Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011–1019
6. Kobayashi K, Inoue A, Maemondo M et al (2009) First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 27(15s (suppl)): abstr 8016
7. Yang JC-H SM, Yamamoto N, O’Byrne KJ et al (2012) A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30: abstr LBA7500
8. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
9. Arcila ME, Oxnard GR, Nafa K et al (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17(5):1169–1180
10. Bean J, Riely GJ, Balak M et al (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14(22):7519–7525
11. Sequist L, Waltman B, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26
12. Turke AB, Zejnullahu K, Wu YL, Song Y et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77–88
13. Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734–1739
14. Doebele RC, Pilling AB, Aisner DL et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5):1472–1482
15. Kim S, Kim TM, Kim DW et al (2013) Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 8(4):415–422
16. Overman MJ, Modak J, Kopetz S et al (2013) Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 31(1):17–22
17. Peppercorn J (2013) Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. J Clin Oncol 31(1):1–2
18. Bunn PA, Hirsch FR, Doebele RC et al (2010) Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol 5(8):1113–1115
19. Hirsch FR, Wynes MW, Gandara DR et al (2010) The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 16(20):4909–4911
20. West H, Oxnard GR, Doebele RC (2013) Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book. 2013.33.e272
21. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
22. Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR Inhibitors. Sci Transl Med 3(75):doi:10.1126/scitranslmed.3002003
23. Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247
24. Browning ET, Weickhardt AJ, Camidge DR (2013) Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J Thorac Oncol 8(3):E21–E22
25. Doebele RC, Lu X, Sumey C et al (2012) Oncogene status predicts patterns of metastatic spread in treatment-naive non small cell lung cancer. Cancer 118(18):4502–4511
26. Yatabe Y, Matsuo K, Mitsudomi T (2011) Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29(22):2972–2977
27. VanderLaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB (2014) Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 84(1):39–44
28. Singh VM, Salunga RC, Huang VJ, Tran Y, Erlander M, Plumlee P, Peterson MR (2014) Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 17(4):322–326
29. Isobe K, Hata Y, Kobayashi K et al (2012) Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res 32(8):3339–3344
30. Rosell R, Molina MA, Serrano MJ (2012) EGFR mutations in circulating tumour DNA. Lancet Oncol 13(10):971–973
31. Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366–377